NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
Clinical Trials
172 trialsNCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT07365592 2026-01-26
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT07340567 2026-01-14
CIRCULATEIII
UNICANCER
Phase 3 Not yet recruiting
NCT07334587 2026-01-12
Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma
Allama Iqbal Medical College
Phase NA Enrolling by invitation
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
NCT07281768 2025-12-15
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT07243938 2025-11-24
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT07158164 2025-11-13
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
Phase 4 Recruiting
NCT05990543 2025-09-08
Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer
Korea University Anam Hospital
Phase 1/2 Active not recruiting
NCT02978612 2025-09-05
ACE
Oslo University Hospital
Phase 2 Completed
NCT03828227 2025-07-18
COLAGE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Active not recruiting
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT06090994 2025-05-07
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
Fudan University
Phase 4 Recruiting
NCT04245865 2025-04-27
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02861300 2024-12-19
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01531595 2024-12-12
AXOAXI
Helsinki University Central Hospital
Phase 2 Active not recruiting
NCT06405139 2024-11-29
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06234007 2024-03-18
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06195670 2024-01-08
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT00958737 2023-09-29
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Unknown
NCT04259944 2023-09-28
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT00202774 2023-04-12
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT05794750 2023-04-06
AK104-IIT-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05797077 2023-04-04
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT01898104 2023-03-24
V-shoRT-R3
National Cancer Institute, Naples
Phase 1/2 Unknown
NCT04304209 2023-02-01
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05699746 2023-01-26
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Zhejiang University
Phase 3 Not yet recruiting
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05236972 2022-12-30
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Phase 3 Recruiting
NCT00954876 2022-10-20
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Phase 2 Withdrawn